Get the Stockscreener App
1.595
2.24%
0.035
After Hours:
1.59
-0.005
-0.31%
Codexis Inc stock is traded at $1.595, with a volume of 1.10M.
It is up +2.24% in the last 24 hours and down -28.79% over the past month.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
See More
Previous Close:
$1.56
Open:
$1.57
24h Volume:
1.10M
Relative Volume:
1.01
Market Cap:
$174.66M
Revenue:
$78.09M
Net Income/Loss:
$-31.99M
P/E Ratio:
-4.3939
EPS:
-0.363
Net Cash Flow:
$-22.12M
1W Performance:
+6.33%
1M Performance:
-28.79%
6M Performance:
+31.82%
1Y Performance:
-47.01%
1-Day Range:
$1.55
$1.62
1-Week Range:
$1.46
$1.66
52-Week Range:
$0.9583
$3.115
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
1.595 | 170.83M | 78.09M | -31.99M | -22.12M | -0.363 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
CDXS Maintained by Piper Sandler -- Price Target Lowered to $8.00 - GuruFocus
CDXS Looks 39.1% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
CDXS Looks 39.1% Undervalued on GF Value™ - GuruFocus
Codexis (NASDAQ:CDXS) Cut to "Sell" at Wall Street Zen - MarketBeat
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Codexis (CDXS) investor Laurence Lytton discloses 5.2% beneficial stake in shares - Stock Titan
Codexis (CDXS) Stock Rallies On Longer Cash Runway Questions Remain - Sahm
Codexis earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Codexis, Inc. Stock 12‑Month Price Target Cut to $6.5, Implies 339% Upside - TradingView
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocatalysis Growth and ECO Synthesis ... - finance.yahoo.com
Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocataly - GuruFocus
Codexis, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
CDXS Looks 40.1% Undervalued on GF Value™ Amidst Challenging Fun - GuruFocus
Codexis narrows Q2 loss, raises $25M to fund GMP expansion - scanx.trade
Codexis Affirms FY26 Sales Guidance Range Amid Stable Outlook - scanx.trade
Transcript : Codexis, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Codexis (NASDAQ:CDXS) Issues Earnings Results - MarketBeat
Codexis Q2 Earnings Call Highlights - MarketBeat
CDXS: Q2 2026 saw revenue of $14.9M, margin gains, new financing, and major ECO Synthesis advances - TradingView
Earnings call transcript: Codexis beats Q2 2026 estimates as shares rise after hours - Investing.com
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
How Did Codexis Inc (CDXS) Perform in Q2? EPS at -0.14, Revenue Beats Estimates; GF Score: 49/100 - GuruFocus
Codexis, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CODEXIS ($CDXS) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Codexis: Q2 Earnings Snapshot - 10TV
Q2 2026 Codexis Inc Earnings Call Transcript - GuruFocus
Codexis Reports Second Quarter 2026 Financial Results - marketscreener.com
Codexis Inc (CDXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Codexis, Inc. expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Price Performance - Yahoo! Finance Canada
Codexis, Inc. Revenue Breakdown – NASDAQ:CDXS - TradingView
Codexis (CDXS) Projected to Release Earnings on Tuesday - MarketBeat
Codexis Inc (CDXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Codexis appoints David Butler to strategic advisory board - Investing.com
Codexis appoints David Butler to strategic advisory board By Investing.com - Investing.com Australia
Codexis Appoints David Butler, PhD, to Strategic Advisory Board - The Manila Times
Press Release: Codexis Appoints David Butler, PhD, to Strategic Advisory Board - Moomoo
Codexis, Inc. (CDXS) investors report 7.3% stake in 7.85M shares - Stock Titan
Codexis to Report Second Quarter 2026 Financial Results on August 11 - The Manila Times
Codexis schedules 4:30 p.m. ET webcast after Aug. 11 close - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Codexis (CDXS), RegenXBio (RGNX) - The Globe and Mail
Codexis Inc (CDXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Codexis Inc (CDXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Codexis prices $25.0M equity offering, nets ~$23.1M after fees - TradingView
Codexis Inc (CDXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Codexis Inc (CDXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CDXS|Codexis Inc|Price:1.455|Chg%:+0.025 - TradingKey
CDXS Stock Falls As Codexis Prices Dilutive Share Offering - timothysykes.com
Codexis: ECO Synthesis And Runway Reset Warrant An Upgrade (Rating Upgrade) - Seeking Alpha
TradingKey - TradingKey
Codexis Market Sentiment - Benzinga España
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Codexis Inc Stock (CDXS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lutz Stefan | Chief Scientific Officer |
Feb 24 '26 |
Sale |
1.13 |
5,862 |
6,641 |
130,421 |
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):